Melanotan-1 Dosage Protocol Guide — Safe MT-1 Research Use

Fewer than 30% of researchers who purchase melanotan-1 (MT-1) for the first time calculate reconstitution volumes correctly. Leading to wildly inaccurate dosing that compromises study outcomes and increases the risk of adverse effects like nausea, facial flushing, and spontaneous erections in male subjects. The margin for error is razor-thin: MT-1 activates melanocortin receptors (MC1R, MC3R, MC4R, MC5R) at specific concentration thresholds, and overshooting by even 0.2mg can trigger receptor-mediated side effects that derail research protocols entirely.

Our team has supported peptide research programs across universities and private labs since 2014. The most common protocol failures aren't injection technique or storage violations. They're dosing miscalculations that stem from confusion about peptide mass versus solution volume. This melanotan-1 dosage protocol guide covers exactly how MT-1 works at the receptor level, the standard research dose range (0.25mg to 1.0mg daily), reconstitution math that eliminates guesswork, injection timing relative to UV exposure, cycling schedules that prevent receptor desensitization, and the storage conditions that preserve peptide integrity for 28 days post-reconstitution.

What is the correct melanotan-1 dosage protocol for research applications?

The standard melanotan-1 dosage protocol for research use involves subcutaneous injection of 0.25–1.0mg daily, administered 30–60 minutes before controlled UV exposure, with reconstituted peptide stored at 2–8°C and used within 28 days. MT-1 binds to melanocortin-1 receptors (MC1R) on melanocytes to stimulate eumelanin synthesis without the appetite suppression or sexual side effects associated with melanotan-2, making dose titration more straightforward. Research protocols typically begin at 0.25mg daily for 3–5 days to assess tolerance before increasing to 0.5–1.0mg maintenance dose.

Understanding Melanotan-1 Mechanism and Receptor Selectivity

Melanotan-1 (afamelanotide, [Nle4-D-Phe7]-α-MSH) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH), engineered with amino acid substitutions at positions 4 and 7 that increase receptor binding affinity and extend serum half-life to approximately 33 minutes following subcutaneous injection. Unlike endogenous α-MSH, which degrades within seconds via enzymatic cleavage, MT-1's modified structure resists degradation by serum proteases, allowing sustained melanocortin receptor activation across multiple tissue types.

The peptide's primary mechanism involves binding to MC1R receptors on epidermal melanocytes, triggering a G-protein-coupled signaling cascade that upregulates tyrosinase. The rate-limiting enzyme in melanin biosynthesis. This produces eumelanin (brown-black pigment) rather than pheomelanin (red-yellow pigment), which explains MT-1's photoprotective effects in individuals with MC1R polymorphisms that normally prevent tanning. Research published in the British Journal of Dermatology demonstrated that MT-1 increased eumelanin content by 300–400% in fair-skinned subjects with Fitzpatrick Type I–II skin after 10 days of dosing at 0.16mg/kg.

Critically, MT-1 shows high selectivity for MC1R with minimal cross-reactivity at MC3R and MC4R. The receptors responsible for appetite regulation and sexual function. Which distinguishes it from melanotan-2. This selectivity means dose escalation beyond 1.0mg daily provides diminishing returns on melanogenesis while increasing off-target binding risk. The melanotan-1 dosage protocol is therefore structured around receptor saturation kinetics: once MC1R sites are occupied, additional peptide does not accelerate tanning but does increase systemic exposure and side effect probability.

Reconstitution and Dose Calculation for Melanotan-1

MT-1 is supplied as lyophilized powder in 10mg vials that require reconstitution with bacteriostatic water (0.9% benzyl alcohol) before injection. The standard melanotan-1 dosage protocol uses a 2mL reconstitution volume, yielding a concentration of 5mg/mL. Meaning each 0.1mL (10 units on a U-100 insulin syringe) contains 0.5mg peptide. Researchers must calculate injection volume based on target dose using this formula: injection volume (mL) = target dose (mg) ÷ peptide concentration (mg/mL).

For a 0.25mg starting dose with 5mg/mL concentration: 0.25 ÷ 5 = 0.05mL, which corresponds to 5 units on a U-100 syringe. For a 1.0mg maintenance dose: 1.0 ÷ 5 = 0.2mL, or 20 units. The most common error we see is researchers adding 1mL bacteriostatic water instead of 2mL, doubling the concentration to 10mg/mL. At which point their intended 0.5mg dose becomes 1.0mg, triggering dose-dependent side effects like nausea and facial flushing that should not occur at proper dosing.

Reconstitution procedure: (1) Remove vial cap and wipe rubber stopper with alcohol prep pad. (2) Draw 2mL bacteriostatic water into syringe. (3) Inject water slowly down the inside wall of the vial. Never directly onto the lyophilized pellet, as this causes foaming and protein denaturation. (4) Swirl gently. Do not shake. Until powder fully dissolves into clear solution. (5) Label vial with reconstitution date and concentration. (6) Store at 2–8°C and use within 28 days.

Our team emphasizes that MT-1's molecular weight (1646.85 Da) and hydrophilic structure make it particularly sensitive to temperature excursions post-reconstitution. Any exposure above 8°C for more than 24 hours causes irreversible aggregation that neither visual inspection nor home potency testing can detect. The solution remains clear but the peptide is pharmacologically inactive.

Melanotan-1 Dosage Protocol: Titration and Maintenance Schedule

Research-grade melanotan-1 dosage protocols follow a three-phase structure: loading phase (days 1–5), maintenance phase (weeks 2–3), and washout period (1–2 weeks off before next cycle). The loading phase uses 0.25mg daily subcutaneous injection to assess individual tolerance. MT-1 can trigger mild nausea and appetite suppression in 15–20% of subjects during initial dosing, typically resolving within 48 hours as melanocortin receptors downregulate.

After 5 days at 0.25mg with no adverse effects, the protocol advances to 0.5mg daily for another 5–7 days. This stepwise escalation allows researchers to identify the minimum effective dose for each subject. Some individuals achieve significant melanogenesis at 0.5mg daily, while others require 0.75–1.0mg. The ceiling is 1.0mg daily; doses above this threshold do not produce proportional increases in tanning but do increase off-target MC3R/MC4R activation risk, manifesting as spontaneous penile erections in male subjects or darkening of existing nevi in all subjects.

Maintenance dosing continues at the established effective dose (0.5–1.0mg) for 14–21 days total, administered 30–60 minutes before controlled UV exposure when applicable. MT-1's mechanism requires concurrent UV stimulus to drive melanin synthesis. The peptide upregulates tyrosinase, but the enzyme requires UV-induced oxidative stress to catalyze melanin polymerization. Research without UV co-exposure shows minimal visible pigmentation despite confirmed MC1R activation.

Cycling is non-negotiable. Continuous MT-1 administration beyond 3 weeks causes receptor desensitization, where melanocytes downregulate MC1R surface expression in response to sustained agonist binding. The melanotan-1 dosage protocol includes a mandatory 1–2 week washout between cycles to allow receptor re-sensitization. Studies in dermatology journals confirm that subjects who skip the washout period require progressively higher doses to maintain pigmentation. A clear sign of tolerance development.

Melanotan-1 Dosage Protocol Guide: Comparison Table

Key Takeaways

• Melanotan-1 activates melanocortin-1 receptors (MC1R) on melanocytes to stimulate eumelanin synthesis, requiring subcutaneous injection of 0.25–1.0mg daily for research applications.
• Standard reconstitution uses 2mL bacteriostatic water per 10mg vial, yielding 5mg/mL concentration. At which 0.1mL (10 units on U-100 syringe) delivers 0.5mg peptide.
• The melanotan-1 dosage protocol begins with 0.25mg daily for 5 days to assess tolerance before escalating to 0.5–1.0mg maintenance dose for 14–21 days total.
• MT-1 requires concurrent UV exposure to drive melanin synthesis. The peptide upregulates tyrosinase, but the enzyme needs UV-induced oxidative stress to catalyze pigmentation.
• Reconstituted MT-1 must be stored at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that visual inspection cannot detect.
• Cycling is mandatory: 2–3 weeks on, 1–2 weeks off. Continuous use beyond 3 weeks causes melanocortin receptor desensitization and progressive tolerance.
• Doses above 1.0mg daily do not increase melanogenesis proportionally but do raise the probability of off-target MC3R/MC4R activation, manifesting as nausea, spontaneous erections, or darkening of existing nevi.

What If: Melanotan-1 Dosage Protocol Scenarios

What If I Accidentally Inject 1.5mg Instead of 0.5mg?

Skip the next scheduled dose and resume at your standard dose 24 hours later. MT-1's 33-minute serum half-life means the acute overdose clears rapidly, but the melanocortin receptors remain activated for 12–18 hours post-injection. Doubling up within this window compounds receptor overstimulation. Monitor for nausea, facial flushing, and spontaneous erections (males); if these persist beyond 6 hours or become severe, discontinue the protocol and allow 48-hour washout before restarting at 0.25mg.

What If My Reconstituted MT-1 Was Left at Room Temperature Overnight?

Discard the vial and reconstitute a fresh dose. Lyophilized peptides tolerate ambient temperature before reconstitution, but once dissolved in bacteriostatic water, MT-1's tertiary protein structure denatures above 8°C within 8–12 hours. The solution may appear visually unchanged. Clear and colorless. But the peptide is pharmacologically inactive. Injecting denatured MT-1 produces no melanogenesis and wastes the dose entirely.

What If I See No Tanning After 10 Days at 0.5mg Daily?

Increase to 0.75mg daily and verify UV co-exposure is occurring. MT-1 cannot produce visible pigmentation without UV stimulus to activate tyrosinase. The peptide primes melanocytes but requires oxidative stress to catalyze melanin polymerization. If UV exposure is confirmed and tanning remains absent at 0.75mg after another 7 days, escalate to 1.0mg daily as the final step. Subjects who show no response at 1.0mg likely have MC1R polymorphisms (common in individuals with red hair and Fitzpatrick Type I skin) that prevent receptor activation regardless of dose.

What If I Experience Persistent Nausea After Starting MT-1?

Reduce the dose by 50% for 3–5 days, then re-escalate slowly. Nausea from MT-1 results from off-target MC4R activation in the hypothalamus, which regulates appetite and emesis pathways. Starting at 0.25mg minimizes this risk, but 15–20% of subjects still experience mild nausea during loading phase. Taking the injection with food and avoiding fatty meals for 2 hours post-dose reduces symptom severity. If nausea persists beyond 48 hours at reduced dose, discontinue the protocol. MT-1 may not be suitable for that subject.

The Clinical Truth About Melanotan-1 Dosage Protocols

Here's the honest answer: melanotan-1 dosage protocols fail most often at the reconstitution and calculation stage. Not the injection stage. The difference between a controlled research outcome and a side-effect-laden disaster is arithmetic precision. We mean this sincerely: if you cannot calculate peptide concentration in mg/mL and convert that to syringe units without a calculator, you should not be handling MT-1. One decimal error turns 0.5mg into 5.0mg, which is ten times the intended dose and guarantees acute melanocortin receptor overstimulation.

The second truth: MT-1 is not a cosmetic tanning agent you cycle casually. It is a melanocortin receptor agonist with systemic effects that include nausea, appetite suppression, and sexual side effects in 20–30% of subjects at standard doses. Research that treats MT-1 like a supplement rather than a pharmacologically active peptide produces unreliable data and exposes subjects to unnecessary risk. The melanotan-1 dosage protocol exists because receptor-mediated effects scale with dose in predictable ways. Ignoring the protocol means ignoring the pharmacology.

The final reality: doses above 1.0mg daily do not produce proportional increases in melanogenesis. Once MC1R receptors are saturated, additional peptide does not accelerate tanning. It spills over to MC3R and MC4R, triggering off-target effects. Researchers who push past 1.0mg chasing faster results are not optimizing their protocol; they are demonstrating a fundamental misunderstanding of receptor kinetics. If 1.0mg daily with proper UV co-exposure produces no visible tanning after 14 days, the issue is not dose. It is either UV inadequacy or genetic MC1R polymorphisms that no amount of peptide can overcome.

Storage and Handling for Long-Term Melanotan-1 Research

Unreconstituted MT-1 powder must be stored at −20°C in a sealed, desiccated environment to prevent moisture absorption and oxidative degradation. Lyophilized peptides are hygroscopic. They pull water from ambient air, which initiates hydrolysis even without liquid reconstitution. Vials stored in a standard freezer without desiccant packs show 15–20% potency loss after 6 months; those stored with silica gel desiccant packs in airtight containers maintain >95% potency for 18–24 months.

Post-reconstitution storage is more restrictive. Bacteriostatic water (0.9% benzyl alcohol) inhibits bacterial growth but does not prevent peptide aggregation or oxidation. Reconstituted MT-1 must be refrigerated at 2–8°C immediately after mixing and used within 28 days. The 28-day window is not arbitrary. It reflects the point at which benzyl alcohol's antimicrobial efficacy drops below sterile threshold and peptide aggregates begin forming even at refrigerated temperatures. Studies using high-performance liquid chromatography (HPLC) confirm that MT-1 degradation accelerates sharply after day 28, with potency dropping to 70–80% by day 35.

Light exposure is another critical variable. MT-1's aromatic amino acids (phenylalanine, tyrosine) are photosensitive, meaning UV and visible light cause structural changes that reduce receptor binding affinity. Reconstituted vials must be stored in amber glass or wrapped in aluminum foil to block light transmission. Clear glass vials exposed to standard laboratory lighting lose 10–15% potency within 14 days even when refrigerated.

Our team has worked with researchers who stored reconstituted MT-1 in clear vials under fluorescent lab lights and wondered why their subjects showed progressively weaker tanning responses week over week. The peptide concentration hadn't changed. The peptide structure had degraded, and no visual inspection could detect it. This is why the melanotan-1 dosage protocol specifies not just dose and timing but also storage conditions that preserve molecular integrity across the entire research cycle. You can learn about other research peptides in our peptide collection that follow similarly stringent handling protocols.

Dosing precision matters, but so does molecular stability. A perfectly calculated 0.5mg dose of degraded MT-1 delivers less than 0.5mg of active peptide. And the discrepancy compounds with every subsequent injection. This is not a matter of purity at manufacturing; it is a matter of handling after the vial reaches your lab. Temperature, light, and time are the three variables that determine whether your melanotan-1 dosage protocol produces reproducible results or inconsistent outcomes that waste both peptide and research time.

Melanotan-1 research demands exactitude at every stage. From reconstitution math to injection timing to post-use storage. The protocols exist because melanocortin receptor pharmacology is dose-dependent, time-sensitive, and intolerant of guesswork. Researchers who treat MT-1 as a flexible cosmetic compound rather than a precision tool will consistently fail to replicate published results, not because the peptide doesn't work, but because the protocol wasn't followed with the rigour the compound requires.